TABLE 5.
Mortality rates (21 day) in 97 ESBL-BSI patients initially treated with antimicrobial agents to which the infecting organism displayed in vitro susceptibility
| Antimicrobial agents administered (n) | No. (%) of patients | OR (95% CI) | P | |
|---|---|---|---|---|
| Nonsurvivors (n = 18) | Survivors (n = 79) | |||
| Aminoglycosides (20) | 5 (27.8) | 15 (19) | 1.48 (0.59-3.66) | 0.40 | 
| β-Lactam-β-lactamase inhibitors (33) | 4 (22.2) | 29 (36.7) | 0.55 (0.19-1.55) | 0.24 | 
| Carbapenems (28) | 1 (5.5) | 27 (34.2) | 0.14 (0.02-1.03) | 0.01 | 
| Ciprofloxacin (16) | 8 (44.4) | 8 (10.1) | 4.05 (1.89-8.65) | <0.001 |